CONGRATULATIONS! BIOTECH AKRO BUYOUT BY NVO BECOMES 213TH ARORA PORTFOLIO BUYOUT
By Nigam Arora
NVO, the maker of weight loss drug Wegovy, is buying AKRO. The deal is for $60 per share. The deal consists of $54 per share in cash to be paid on closing and $6 per share in cash upon U.S. regulatory approval of efruxifermin drug cirrhosis.
What To Do Now
The stock is trading at $55.25 as of this writing in the premarket. The contingent value rights (CVR) are likely to be illiquid and not traded. Those deciding to hold have a good probability of ultimately receiving $6 per share in share for CVR. To hold or to take profits now is a matter of personal preference.… Please click here or the title below to read more.
October 9, 2025